Join NY Giants great Harry Carson and Hackensack Meridian Health, Screenings for Prostate Cancer, High Blood Pressure, Diabetes, Asthma & Lung Disease and More
Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine’s Game Changer vehicles, which bring health education and free screenings for many cancer types to South Florida communities in need, are for the first time offering prostate-specific antigen (PSA) screening for prostate cancer.
In a new study published in Molecular Cancer Research, Mayo Clinic researchers identified critical genomic changes in response to abiraterone acetate/prednisone, a standard treatment option for men with progressive, incurable and castration-resistant prostate cancer.
Moffitt Cancer Center has conducted the first prospective study to investigate genomic biomarkers associated with aggressive disease in African American men with prostate cancer. The study results were published in the Journal of the National Cancer Institute.
A new study from the University of Michigan Rogel Cancer Center suggests androgen receptor inhibitors can fundamentally rewire and reshape how prostate tumors function, and in certain cases even make them more aggressive. These findings will be published in Nature Communications on Sept. 15.
A new study published by University of Kentucky Markey Cancer Center researchers suggests that the common steroid betamethasone could be used to reduce unwanted side effects of radiation treatments for prostate cancer.
Men with early, curable stages of prostate cancer are missing opportunities to have their cancer detected because national guidelines and media health campaigns focus on urinary symptoms despite a lack of scientific evidence, say experts at the University of Cambridge.
Hormone therapy for prostate cancer increases the risk of cardiovascular disease-related death especially in older men, according to a population study involving more than 13,000 patients.
Clinical advances include treating hematologic cancers with effective targeted therapies, circulating tumor DNA as a biomarker for recurrence with colorectal liver metastases, and using magnetic resonance imaging (MRI) to guide surgical decisions for patients with lateral pelvic lymph node metastases in rectal cancer. Laboratory findings offer new understanding of the pancreatic cancer immune microenvironment, melanoma cell states, TP53 mutation status in acute myeloid leukemia (AML), and potential targets for metastatic prostate cancer and GNAS-mutant colorectal cancer.
Smilow Cancer Hospital is now offering a new surgical option for prostate cancer treatment unavailable elsewhere in Connecticut, and still rare throughout the United States. The beneficiaries are men in need of a prostatectomy, a procedure in which the prostate is partially or completely removed to eradicate localized cancer.
Researchers have found a significant difference in the gut microbiota of men with prostate cancer, compared with those who have benign biopsies.
Researchers in Center of Excellence for Evolutionary Therapy at Moffitt Cancer Center are thinking outside the box and studying an alternative approach called adaptive therapy that is based on evolutionary principles and mathematical modeling. In a new article in eLife, the researchers report updated results from a pilot clinical trial evaluating an adaptive therapy approach using the drug abiraterone to treat patients with metastatic castrate-resistant prostate cancer.
Researchers at Case Western Reserve University and the University of Washington expect to gain valuable new insights into highly aggressive prostate cancer by combining Artificial Intelligence (AI)-powered diagnostic imaging with three-dimensional (3D) tissue imaging.
Adding short-term hormone therapy and pelvic lymph node radiotherapy to standard of care prostatectomy surgical bed treatment benefits prostate cancer patients whose prostate-specific antigen (PSA) levels are rising post prostatectomy, according to an international study led by Alan Pollack, M.D.,…
In a new article published in Science Translational Medicine, Moffitt Cancer Center researchers reveal a mechanism by which prostate cancer cells become resistant through molecular modification of the androgen receptor protein and identify a potential treatment approach that could overcome this resistance.
Radiation is an effective treatment for prostate cancer. Ronald D. Ennis, MD,Professor and Vice Chair of Network Integration and Quality, Department of Radiation Oncology at Rutgers Cancer Institute, along with Lara Hathout, MD, FRCPC, radiation oncologist and director of Brachytherapy at Rutgers Cancer Institute and associate Professor of radiation oncology at Rutgers Robert Wood Johnson Medical School share more
Henry Ford Health is the first in the world to complete a full course of patient treatments using the latest advancement in magnetic resonance (MR)-guided radiation therapy, which integrates real-time magnetic resonance imaging (MRI) and linear acceleration to deliver precise and accurate radiation treatment more rapidly than ever before.
Eric Small, MD, has been announced as one of the winners of the 10th annual Giants of Cancer Care® awards. Small is being recognized for his achievements in the clinical practice and research of genitourinary cancers.
Practice-changing research from Cedars-Sinai Cancer shows that a combination of androgen deprivation therapy—a commonly used hormone injection—plus pelvic lymph node radiation, kept nearly 90% of clinical trial patients’ prostate cancer at bay for five years. The findings were published in the peer-reviewed journal The Lancet.
Zulu Social Aid and Pleasure Club Presents Men’s Health Fair, Sponsored by Ochsner Xavier Institute of Health Equity and Research.
A Cleveland Clinic-led research team uncovered how tumors circumvent prostate cancer therapy and identified a promising new strategy for treatment. Findings were published in Proceedings of the National Academy of Sciences (PNAS). Antiandrogen strategies remain the backbone for advanced prostate…
Research underscores the need to subdivide Hispanics and other racial and ethnic groups to fully understand actual disparities. Brandon A. Mahal, M.D. In a massive study, clinical researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School…
Cedars-Sinai urology experts will present their latest advances in urologic medicine at the annual scientific meeting of the American Urological Association (AUA) in New Orleans May 13-16, 2022. Among over 2,200 abstracts, one by Alexandra Dubinskaya, MD, a female pelvic medicine and reconstructive surgery (FPMRS) specialist—Is It Time for FPMRS to Prescribe Vibrators?—was selected to be included in the 117th AUA press session on May 13, 2022, at 9 a.m. CT.
Henry Ford Health is the first in Michigan to offer Robotic High Intensity Focused Ultrasound (HIFU) for the treatment of localized prostate cancer. This non-surgical treatment option spares surrounding healthy tissue, while allowing for a quicker treatment time and recovery for the patient.
This tipsheet highlights the latest medical discoveries and faculty news at Cedars-Sinai. Links to full news releases are included with each item.
In a large study led by Yale Cancer Center, more men received a prostate-specific antigen or PSA test to detect prostate cancer following revisions to the recommendation by the U.S. Preventative Services Task Force on screening. The results also showed significant increases in PSA testing among older men, a group for whom screening is not routinely recommended.
Researchers have developed a new treatment to be used in combination with radiotherapy that could significantly improve treatment outcomes for men with locally advanced prostate cancer.
A new study from Washington University School of Medicine in St. Louis has identified an RNA molecule that suppresses prostate tumors. The scientists found that prostate cancers develop ways to shut down this RNA molecule to allow themselves to grow.
The National Comprehensive Cancer Network’s Oncology Research Program to oversee projects focused on the use of enzalutamide in treating people with prostate cancer.
The immune checkpoint protein B7-H3 may be a promising new target for immunotherapy in treatment-resistant prostate cancers, according to two new studies led by researchers at the Johns Hopkins Kimmel Cancer Center. The studies were presented recently at the European Society for Medical Oncology (ESMO) 2021 Conference.
Cleveland Clinic researchers have shown for the first time that diet-associated molecules in the gut are associated with aggressive prostate cancer, suggesting dietary interventions may help reduce risk. Findings from the study were published in Cancer Epidemiology, Biomarkers & Prevention.
African American men are at the highest risk for both developing and dying from prostate cancer. It is essential that this population take preventative measures and seek appropriate treatment if diagnosed.
A new meta-analysis finds that a genetic biomarker test accurately predicts how men with high-risk prostate cancer will respond to treatment with radiation and hormone therapy. The study, which examined biopsy samples collected from three large, randomized clinical trials, indicates that physicians potentially can use genetic test scores to personalize treatment for men with the most aggressive form of prostate cancer. Findings will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
Using fewer—but higher—doses of radiation to treat men with prostate cancer who had their prostates removed does not increase long-term side effects or lower their quality of life compared to conventional radiation treatment, a new, multi-institutional clinical trial shows.
Two research teams have developed new noninvasive tests that use either blood or saliva samples to diagnose cases of colorectal cancer or prostate cancer, respectively. Presented today at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo, these tests could facilitate screening efforts for colorectal cancer and allow clinicians to better distinguish early-stage prostate cancer from more benign prostate conditions.
As Prostate Cancer Awareness Month comes to a close, researchers want to circulate the message that some gene mutations linked to breast and ovarian cancer are also associated with prostate cancer.
Scientists have identified two subtypes of metastatic prostate cancer that respond differently to treatment, information that could one day guide physicians in treating patients with the therapies best suited to their disease.
New findings by researchers at Yale Cancer Center show the drug combination of nivolumab and rucaparib shows clinical activity for patients with chemotherapy-naïve, metastatic castration resistant prostate cancer.
A paper detailing the method that led to the US Food and Drug Administration approval for PSMA PET imaging, which was led by UCLA and UCSF and their nuclear medicine teams, was recently published in JAMA Oncology.
For men with “low-risk” prostate cancer initially managed with active surveillance, cancer-related factors such as tumor grade and size are key risk factors for conversion to active treatment, reports a study in The Journal of Urology®, an Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.
Over the last decade, advancements have been made in the diagnosis and treatment of prostate cancer that are saving more lives. Tina Mayer, MD, a medical oncologist in the Prostate Cancer Program at Rutgers Cancer Institute of New Jersey shares some insight.
Tina Mayer, MD, medical oncologist in the Prostate Cancer Program at Rutgers Cancer Institute of New Jersey and an associate professor of medicine at Rutgers Robert Wood Johnson Medical School, shares information about prostate health.
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts.
Physicians and scientists from UCLA will be joining thousands of urology experts on Sept. 10 to Sept. 13 for the virtual American Urological Association (AUA) Annual Meeting.
Nearly half of men initially managed with active surveillance for “low-risk” prostate cancer transition to definitive treatment – such as surgery or radiation therapy – within a few years after diagnosis, reports a study in The Journal of Urology®, an Official Journal of the American Urological Association (AUA).
The Intermediate Clinical Endpoints of Cancer of the Prostate (ICECaP) working group, led by Dana-Farber Cancer Institute researchers, is being honored by the American Statistical Association (ASA) with the 2021 Statistical Partnerships Among Academe, Industry, and Government (SPAIG) Award.
Researchers led by the University of Michigan Rogel Cancer Center identified an inhibitor that showed promise against metastatic castration-resistant prostate cancer cells.
A new, University of Michigan-led study analyzing data from more than 850 patients across the state of Michigan found a commercially available genomic test known as Decipher Biopsy may help identify patients who are at high risk of prostate cancer progression.
New York, NY (July 23, 2021) — Mount Sinai researchers have developed a therapeutic agent that shows high effectiveness in vitro at disrupting a biological pathway that helps cancer survive, according to a paper published in Cancer Discovery , a…
Cardiovascular disease and cancer, the nation’s top two killers, share common ground like obesity and chronic inflammation, as well as a disproportionate impact on Black Americans. A new American Heart Association-funded center at the Medical College of Georgia is working…